

Notice of References Cited	Application/Control No. 10/826,679	Applicant(s)/Patent Under Reexamination BALENDIRAN, GANESARATNAM	
	Examiner James D. Anderson	Art Unit 1614	Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Mulligan et al. Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. Br. J. Cancer, 1991, vol. 64, pages 1035-1038. ✓
	V	Saidi et al. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Molecular Cancer, 2006, vol. 5, pages 1-14 (printed from http://www.molecular-cancer.com/content/5/1/13 on 4/17/2007). ✓
	W	Grabacka et al. Inhibition of melanoma metastases by fenofibrate. Arch. Dermatol. Res., 2004, vol. 296, pages 54-58. ✓
	X	Tsubouchi et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-g agonists through induction of apoptosis. Biochemical and Biophysical Research Communications, 2000, vol. 270, pages 400-405. ✓

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/826,679	Applicant(s)/Patent Under Reexamination BALENDIRAN, GANESARATNAM	
	Examiner James D. Anderson	Art Unit 1614	Page 2 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Newman et al. Carcinogenicity of lipid-lowering drugs. JAMA, 1996, vol. 275, pages 55-60. ✓
	V	Scatena et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death and Differentiation, 1999, vol. 6, pages 781-787.
	W	Nomura et al. Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate. Surg. Today, 1996, vol. 26, pages 89-94. ✓
	X	Hirst et al. Altered radiosensitivity in a mouse carcinoma after administration of clofibrate and bezafibrate. Radiotherapy and Oncology, 1989, vol. 15, pages 55-61. ✓

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/826,679	Applicant(s)/Patent Under Reexamination BALENDIRAN, GANESARATNAM	
	Examiner James D. Anderson	Art Unit 1614	Page 3 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Calais et al. In situ radiosensitization induced by clofibrate administration: single dose and fractionated studies. Radiotherapy and Oncology, 1991, vol. 22, pages 99-103. ✓
	V	Cohen, P.R. The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia. Clin. Investig., 1993, vol. 71, pages 74-77.
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.